Vera Therapeutics SVP exercises options for 10,000 shares

Vera Therapeutics, Inc. senior vice president of finance and chief accounting officer Joseph R. Young exercised stock options to acquire 10,000 shares of Class A common stock at an exercise price of $3.9396 per share on March 13, 2026.

Rhea-AI Filing Summary

Vera Therapeutics, Inc. senior vice president of finance and chief accounting officer Joseph R. Young exercised stock options to acquire 10,000 shares of Class A common stock at an exercise price of $3.9396 per share on March 13, 2026.

Following the transactions, he directly owns 75,754 shares of Class A common stock and holds 38,589 stock options. The filing notes that 1,032 of his shares were acquired through the company’s 2021 Employee Stock Purchase Plan, and the option grant vests over time, with a portion vesting monthly.

Insider Trade Summary

10,000 shares exercised/converted

Exercise 2 txns

Insider Young Joseph R

Role SVP, FINANCE, CHIEF ACCT OFFCR

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	10,000	$0.00	$0.00
Exercise	Class A Common Stock	10,000	$3.9396	$39K

Holdings After Transaction: Stock Option (right to buy) — 38,589 contracts (Direct); Class A Common Stock — 75,754 shares (Direct)

Footnotes (2)

1. F1. Includes 1,032 shares acquired pursuant to the Company's 2021 Employee Stock Purchase Plan.
2. F2. 1/4 of the shares subject to the option vested on March 9, 2022, and 1/48 of the shares vest monthly thereafter.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Vera Therapeutics (VERA) report for Joseph R. Young?

Joseph R. Young exercised stock options to acquire 10,000 shares of Vera Therapeutics Class A common stock. The options were exercised at an exercise price of $3.9396 per share, converting derivative holdings into directly owned common shares without any reported share sales.

How many Vera Therapeutics (VERA) shares does Joseph R. Young hold after this Form 4?

After the reported transactions, Joseph R. Young directly owns 75,754 shares of Class A common stock. He also has 38,589 stock options remaining from the same grant, reflecting a mix of current equity ownership and unexercised options tied to continued vesting.

What was the exercise price of the options used by Vera Therapeutics (VERA) executive Joseph R. Young?

The stock options exercised by Joseph R. Young had an exercise price of $3.9396 per share. Exercising these options allowed him to convert 10,000 option rights into 10,000 shares of Class A common stock on March 13, 2026, as disclosed in the Form 4.

Did Vera Therapeutics (VERA) SVP Joseph R. Young sell any shares in this Form 4 filing?

The Form 4 shows no open-market sales by Joseph R. Young. It reports only an option exercise, where 10,000 stock options were converted into 10,000 shares of Class A common stock, increasing his directly owned share position without a corresponding sale transaction.

How do Joseph R. Young’s Vera Therapeutics (VERA) options vest according to the filing?

The option grant vests over time, with an initial and monthly schedule. One quarter of the shares subject to the option vested on March 9, 2022, and one forty-eighth of the shares vest monthly thereafter, linking continued vesting to his ongoing service with the company.

What portion of Joseph R. Young’s Vera Therapeutics (VERA) shares came from the employee stock purchase plan?

The filing notes that 1,032 of Joseph R. Young’s shares were acquired through the 2021 Employee Stock Purchase Plan. This indicates part of his holdings resulted from voluntary participation in the company’s employee share purchase program in addition to option-based awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/16/2026 - 06:52 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Young Joseph R

(Last) (First) (Middle)

C/O VERA THERAPEUTICS, INC.

2000 SIERRA POINT PARKWAY, SUITE 1200

(Street)

BRISBANE CA 94005

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vera Therapeutics, Inc. [ VERA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, FINANCE, CHIEF ACCT OFFCR

3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	03/13/2026		M		10,000	A	$3.9396	75,754(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$3.9396	03/13/2026		M			10,000	(2)	04/13/2031	Class A Common Stock	10,000	$0	38,589	D

Explanation of Responses:

1. Includes 1,032 shares acquired pursuant to the Company's 2021 Employee Stock Purchase Plan.

2. 1/4 of the shares subject to the option vested on March 9, 2022, and 1/48 of the shares vest monthly thereafter.

	/s/ Joseph R. Young	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.